TiGenix meets in Crohn's Phase III

TiGenix N.V. (Euronext:TIG) gained EUR 0.17 (24%) to EUR 0.88 on Monday after its Cx601 met the primary endpoint in the Phase III ADMIRE-CD trial to treat complex perianal fistulas in Crohn's disease patients who did not respond to prior therapies. A single injection of Cx601 was superior to placebo in achieving combined remission of perianal fistulas (49.5% vs. 34.3%; p<0.025) after 24 weeks in the study's 212-patient intent-to-treat population.

TiGenix said treatment-emergent adverse events were similar between Cx601 and placebo. Cx601 is a suspension of allogeneic expanded adipose-derived stem cells. ...